Acquisition by Shafmaster Madge K. of 60000 shares of ProMIS Neurosciences at 1.2511 subject to Rule 16b-3

PMN Stock  USD 1.03  0.07  7.29%   
About 71 percent of all ProMIS Neurosciences' investors are curious in acquiring. The analysis of the overall investor sentiment regarding ProMIS Neurosciences suggests that quite a few traders are confidant. ProMIS Neurosciences' investing sentiment overview a quick insight into current market opportunities from investing in ProMIS Neurosciences. Many technical investors use ProMIS Neurosciences stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by ProMIS Neurosciences Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at finance.yahoo.com
Yahoo News
  
Acquisition of 60000 common shares at 1.2511 of ProMIS Neurosciences by Shafmaster Madge K. on 20th of September 2024. This event was filed by ProMIS Neurosciences with SEC on 2024-09-20. Statement of changes in beneficial ownership - SEC Form 4

ProMIS Neurosciences Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards ProMIS Neurosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

ProMIS Neurosciences Fundamental Analysis

We analyze ProMIS Neurosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ProMIS Neurosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ProMIS Neurosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Beta

Beta Comparative Analysis

ProMIS Neurosciences is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

ProMIS Neurosciences Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ProMIS Neurosciences stock to make a market-neutral strategy. Peer analysis of ProMIS Neurosciences could also be used in its relative valuation, which is a method of valuing ProMIS Neurosciences by comparing valuation metrics with similar companies.

Peers

ProMIS Neurosciences Related Equities

FENCFennec Pharmaceuticals   12.71   
0%
100.0%
ZHCLFZenith Capital   10.00   
0%
78.0%
CMPXCompass Therapeutics   7.97   
0%
62.0%
GANXGain Therapeutics   6.17   
0%
48.0%
CGEMCullinan Oncology   2.62   
0%
20.0%
HLVXHillevax   2.20   
0%
17.0%
GLUEMonte Rosa   1.68   
0%
13.0%
OPTOpthea   0.96   
0%
7.0%
NAMSNewAmsterdam Pharma   0.40   
0%
3.0%
STROSutro Biopharma   0.79   
6.0%
0%
CUECue Biopharma   0.97   
7.0%
0%
NAMSWNewAmsterdam Pharma   1.33   
10.0%
0%
IVAInventiva   1.50   
11.0%
0%
BIVIBiovie   1.93   
15.0%
0%
INABIn8bio   3.03   
23.0%
0%
CNTACentessa Pharmaceuticals   6.32   
49.0%
0%
When determining whether ProMIS Neurosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProMIS Neurosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Promis Neurosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Promis Neurosciences Stock:
Check out ProMIS Neurosciences Hype Analysis, ProMIS Neurosciences Correlation and ProMIS Neurosciences Performance.
To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.04
Revenue Per Share
0.001
Return On Assets
(4.81)
Return On Equity
(10.99)
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.